scholarly journals The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective

2018 ◽  
Vol 127 (2) ◽  
pp. 72-78 ◽  
Author(s):  
Kelvin Young ◽  
Gilda da Cunha Santos ◽  
Paul Card ◽  
Natasha Leighl
Keyword(s):  
Lung Cancer ◽  
Personalized Medicine ◽  
Molecular Testing ◽  
Clinical Perspective ◽  
And Personalized Medicine

scholarly journals Cancer oriented biobanks: A comprehensive review

2018 ◽  
Author(s):  
Shankargouda Patil ◽  
Barnali Majumdar ◽  
Kamran Habib Awan ◽  
Gargi S. Sarode ◽  
Sachin C. Sarode ◽  
...  
Keyword(s):  
Cancer Research ◽  
Personalized Medicine ◽  
Biomarker Discovery ◽  
Review Paper ◽  
Comprehensive Review ◽  
Therapeutic Drugs ◽  
The World ◽  
And Personalized Medicine

Biobanks provide a platform for innovative biomedical research and has improvised translational and personalized medicine to a great extent. Time 2009 published 10 ideas changing the world right now with biobanks on the list emphasizing its role in discovery and development of new therapeutic drugs. They form the cornerstone, providing resources for future investigations and biomarker discovery to understand the effects of genetic, environmental and lifestyle factors on human morbidity, mortality and health. The aim of this review paper is to understand the role of biobanking in cancer research, the challenges faced and strategies to overcome these, for long term and sustainable research in the field of oncology.

The Emerging Role of Molecular Testing in Non–Small Cell Lung Cancer

2017 ◽  
Vol 8 (6) ◽  
Author(s):  
Patrick J. Kiel, PharmD, BCPS, BCOP ◽  
Liang Cheng, MD ◽  
Anna Livers-Ertel, ANP-BC, MSN, OCN ◽  
Gregory Durm, MD
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Molecular Testing ◽  
Small Cell Lung

scholarly journals The growing role of precision and personalized medicine for cancer treatment

TECHNOLOGY ◽  
2018 ◽  
Vol 06 (03n04) ◽  
pp. 79-100 ◽  
Author(s):  
Paulina Krzyszczyk ◽  
Alison Acevedo ◽  
Erika J. Davidoff ◽  
Lauren M. Timmins ◽  
Ileana Marrero-Berrios ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Cancer Treatment ◽  
Cancer Care ◽  
Patient Population ◽  
Effective Drug ◽  
Regulatory Agencies ◽  
Cancer Treatments ◽  
Disease Heterogeneity ◽  
And Personalized Medicine

Cancer is a devastating disease that takes the lives of hundreds of thousands of people every year. Due to disease heterogeneity, standard treatments, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors can have different underlying genetic causes and may express different proteins in one patient versus another. This inherent variability of cancer lends itself to the growing field of precision and personalized medicine (PPM). There are many ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are already available to link these differences to an effective drug. It is clear that PPM cancer treatments can result in immense patient benefits, and companies and regulatory agencies have begun to recognize this. However, broader changes to the healthcare and insurance systems must be addressed if PPM is to become part of standard cancer care.

Sign in / Sign up

Export Citation Format

Share Document